Conclusion
To conclude, the findings of reduced neonatal costs associated with the use of CTG+STan in an Australian context (ableit non-significant) are consistent with other studies performed elsewhere. Although no reduction of maternal costs has been demonstrated, and with no difference in the primary clinical outcome of emergency caesarean section, the reduced neonatal costs and the delivery of babies requiring less critical care suggest that the addition of STan to CTG warrants further investigation, and may be cost effective. STan may have a role in helping to address the significant safety challenges facing the maternity services.